Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sagar Dholariya, Deepak Parchwani, Siddhartha Dutta & Ragini Singh. (2023) Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology 16:1, pages 61-71.
Read now
Read now
Yongjing Ju, Duzhen Zhang & Junyi Yang. (2022) Dasiglucagon for treating severe hypoglycemia in patients with diabetes. Expert Review of Clinical Pharmacology 15:7, pages 799-803.
Read now
Read now
Shujuan Li, Ying Hu, Xueying Tan, Dongwei Wang, Jingbo Hu, Ping Zou & Li Wang. (2020) Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opinion on Pharmacotherapy 21:11, pages 1311-1318.
Read now
Read now
Brian Leinwand, Michael Johnsrud, Anh Nguyen, James Meyer & Ken Johnson. (2020) A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model. Journal of Medical Economics 23:7, pages 744-750.
Read now
Read now
Brett Newswanger, Steven Prestrelski & Anthony D. Andre. (2019) Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opinion on Drug Delivery 16:9, pages 1015-1025.
Read now
Read now
Charles Shaefer, Debbie Hinnen & Christopher Sadler. (2016) Hypoglycemia and diabetes: increased need for awareness. Current Medical Research and Opinion 32:9, pages 1479-1486.
Read now
Read now
Articles from other publishers (79)
Brian P Cary, Xin Zhang, Jianjun Cao, Rachel M Johnson, Sarah J Piper, Elliot J Gerrard, Denise Wootten & Patrick M Sexton. (2023) New Insights into the Structure and Function of Class B1 GPCRs. Endocrine Reviews 44:3, pages 492-517.
Crossref
Crossref
Simon Heller, Tadej Battelino, Timothy S. Bailey, Thomas R. Pieber, Ulrike Hövelmann, Leona Plum‐Mörschel, Anita E. Melgaard, Ronnie Aronson, Linda A. DiMeglio, Thue Johansen & Thomas Danne. (2023) Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes, Obesity and Metabolism 25:5, pages 1351-1360.
Crossref
Crossref
Risa Nasu, Douglas E. James, Emmanuel Chigutsa, Parag Garhyan & Yukiko Nagai. (2023) Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation. Pediatric Drugs 25:3, pages 377-387.
Crossref
Crossref
Cho Rim Kim, Jae Hoon Han, Min Ji Kim, Myoung Ju Kim, Se‐Na Kim, Yong Chan Cho, Han Bi Ji, Chang Hee Min, Cheol Lee & Young Bin Choy. (2023) Implantable device with magnetically rotating disk for needle‐free administrations of emergency drug. Bioengineering & Translational Medicine 8:3.
Crossref
Crossref
Adel AlTowayan, Seetah Alharbi, Maryam Aldehami, Rand Albahli, Sama Alnafessah & Abeer M Alharbi. (2023) Awareness Level of Hypoglycemia Among Diabetes Mellitus Type 2 Patients in Al Qassim Region. Cureus.
Crossref
Crossref
David M. MaahsPriya PrahaladDarja Šmigoc SchweigerShlomit Shalitin. (2023) Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology & Therapeutics 25:S1, pages S-118-S-145.
Crossref
Crossref
Allyson S. Hughes, Katherine Chapman, Jeoffrey Bispham, Jeannett Dimsits, Stuart Weinzimer, Wendy Wolf & Nazanin Heydarian. (2022) “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal of Clinical & Translational Endocrinology 30, pages 100310.
Crossref
Crossref
Yong Ho Heo, Jung Kuk Kim, Jong Suk Lee, Sang-Hyun Lee, Seung-Hyun Shin, In Young Choi & Ha Hyung Kim. (2022) A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism. Scientific Reports 12:1.
Crossref
Crossref
Karzan Jalal Salih, Dana Khdr Sabir & Hayman Jalal Abdoul. (2022) Glycolysis Regulation to Maintain Blood Glucose Homeostasis. Kurdistan Journal of Applied Research, pages 114-124.
Crossref
Crossref
Mark Hoffman, Molly Murphy, Michael C. Koester, Emily C. Norcross & Sam T. Johnson. (2022) Use of Lifesaving Medications by Athletic Trainers. Journal of Athletic Training 57:7, pages 613-620.
Crossref
Crossref
Nakiya Whitfield, Patrick Gregory, Beiyu Liu, Susan Spratt & Benjamin H. Smith. (2022) Impact of pharmacist outreach on glucagon prescribing. Journal of the American Pharmacists Association 62:4, pages 1384-1388.e1.
Crossref
Crossref
Andrea Orlandin, Ivan Guryanov, Lucia Ferrazzano, Barbara Biondi, Francesca Biscaglia, Claudia Storti, Marzio Rancan, Fernando Formaggio, Antonio Ricci & Walter Cabri. (2022) Carbodiimide-Mediated Beckmann Rearrangement of Oxyma-B as a Side Reaction in Peptide Synthesis. Molecules 27:13, pages 4235.
Crossref
Crossref
Brian Lu, Amin GhavamiNejad, Jackie Fule Liu, Jason Li, Sako Mirzaie, Adria Giacca & Xiao Yu Wu. (2022) “Smart” Composite Microneedle Patch Stabilizes Glucagon and Prevents Nocturnal Hypoglycemia: Experimental Studies and Molecular Dynamics Simulation. ACS Applied Materials & Interfaces 14:18, pages 20576-20590.
Crossref
Crossref
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Amirhossein Sahebkar, Yassine Riadi, Rahul Shukla & Prashant Kesharwani. (2022) Stimuli-Responsive Microneedles as a Transdermal Drug Delivery System: A Demand-Supply Strategy. Biomacromolecules 23:4, pages 1519-1544.
Crossref
Crossref
Jordan HinaharaStuart A WeinzimerEmilie R BromleyThomas F GossDavid M KendallMette Hammer. (2022) Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal of Managed Care & Specialty Pharmacy 28:4, pages 461-472.
Crossref
Crossref
Heather L. Stuckey, Urvi Desai, Sarah B. King, Lyuba Popadic, William Levinson, Noam Y. Kirson, Emily R. Hankosky & Beth Mitchell. (2021) The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: “What am I going to do?”. Diabetic Medicine 39:4.
Crossref
Crossref
Naila Celeste BaileyJeannett DimsitsMette HammerDavid M. KendallTimothy S. Bailey. (2022) A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia. Diabetes Technology & Therapeutics 24:4, pages 231-240.
Crossref
Crossref
Anjana Bairavi Maheswaran, Renee Petzel Gimbar, Yuval Eisenberg & Janet Lin. (2022) Hypoglycemic Events in the Emergency Department. Endocrine Practice 28:4, pages 372-377.
Crossref
Crossref
Beatrice Osumili, Esther Artime, Beth Mitchell, Miriam Rubio-de Santos, Silvia Díaz-Cerezo, Marga Giménez, Erik Spaepen, Helen Sharland & William J. Valentine. (2022) Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain. Diabetes Therapy 13:4, pages 775-794.
Crossref
Crossref
Katherine Chapman, Allyson S. Hughes, Jeoffrey Bispham, Carolina Leon, Huyen Nguyen & Wendy A. Wolf. (2022) Emergency Glucagon: a Focused Review of Psychosocial Experiences of Rescue Drugs for Type 1 Diabetes. Current Diabetes Reports 22:4, pages 189-197.
Crossref
Crossref
Yahiya Y. Syed. (2022) Dasiglucagon in severe hypoglycemia: a profile of its use. Drugs & Therapy Perspectives 38:3, pages 105-111.
Crossref
Crossref
Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie M. Ballantyne, Joshua A. Beckman, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew J. Budoff, Javed Butler, Samuel Dagogo-Jack, Ian H. de Boer, Ralph A. DeFronzo, Robert H. Eckel, Daniel Einhorn, Vivian A. Fonseca, Jennifer B. Green, George Grunberger, Chris Guerin, Silvio E. Inzucchi, Paul S. Jellinger, Mikhail N. Kosiborod, Pamela Kushner, Norman Lepor, Christian W. Mende, Erin D. Michos, Jorge Plutzky, Pam R. Taub, Guillermo E. Umpierrez, Muthiah Vaduganathan & Matthew R. Weir. (2022) DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and its Complications 36:2, pages 108101.
Crossref
Crossref
Dalal Al Hasan, Ameen Yaseen, Mohammad Al Roudan & Lee Wallis. (2021) Epidemiology and outcomes from severe hypoglycemia in Kuwait: a prospective cohort study. BMC Emergency Medicine 21:1.
Crossref
Crossref
Bo Xu, Gaorui Tang & Zhen Chen. (2021) Dasiglucagon: an effective medicine for severe hypoglycemia. European Journal of Clinical Pharmacology 77:12, pages 1783-1790.
Crossref
Crossref
Ananta Addala, Dessi P Zaharieva, Angela J Gu, Priya Prahalad, David Scheinker, Bruce Buckingham, Korey K Hood & David M Maahs. (2021) Clinically Serious Hypoglycemia Is Rare and Not Associated With Time-in-range in Youth With New-onset Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism 106:11, pages 3239-3247.
Crossref
Crossref
Mengjie Liu, Peishen Zhao, Md Hemayet Uddin, Wenyi Li, Feng Lin, Chaitra Chandrashekar, Yuji Nishiuchi, Yasuhiro Kajihara, Briony E. Forbes, Denise Wootten, John D. Wade & Mohammed Akhter Hossain. (2021) Chemical Synthesis and Characterization of a Nonfibrillating Glycoglucagon. Bioconjugate Chemistry 32:10, pages 2148-2153.
Crossref
Crossref
Mark P Christiansen, Martin Cummins, Steven Prestrelski, Nicole C Close, Anh Nguyen & Khaled Junaidi. (2021) Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. BMJ Open Diabetes Research & Care 9:1, pages e002137.
Crossref
Crossref
Timothy S. Bailey, Julie Willard, Leslie J. Klaff, Jenine Yager Stone, Anita Melgaard & Ramin Tehranchi. (2021) Dasiglucagon, a next‐generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double‐blind trial. Diabetes, Obesity and Metabolism 23:10, pages 2329-2335.
Crossref
Crossref
F. Javier Ampudia-Blasco, Esther Artime, Silvia Díaz, Miriam Rubio, Jesús Reviriego, Beth Mitchell, Beatrice Osumili, Mark Peyrot, Robin Pokrzywinski, Erik Spaepen & Frank Snoek. (2021) Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinología, Diabetes y Nutrición 68:8, pages 557-566.
Crossref
Crossref
F. Javier Ampudia-Blasco, Esther Artime, Silvia Díaz, Miriam Rubio, Jesús Reviriego, Beth Mitchell, Beatrice Osumili, Mark Peyrot, Robin Pokrzywinski, Erik Spaepen & Frank Snoek. (2021) Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinología, Diabetes y Nutrición (English ed.) 68:8, pages 557-566.
Crossref
Crossref
Francesca Porcellati, Stefania Di Mauro, Alessio Mazzieri, Alessandra Scamporrino, Agnese Filippello, Michelantonio De Fano, Carmine Giuseppe Fanelli, Francesco Purrello, Roberta Malaguarnera & Salvatore Piro. (2021) Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?. Biomolecules 11:9, pages 1281.
Crossref
Crossref
Tadej Battelino, Ramin Tehranchi, Timothy Bailey, Klemen Dovc, Anita Melgaard, Jenine Yager Stone, Stephanie Woerner, Thekla von dem Berge, Linda DiMeglio & Thomas Danne. (2021) Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatric Diabetes 22:5, pages 734-741.
Crossref
Crossref
Giulia Mazzoccanti, Simone Manetto, Michele Bassan, Marco Macis, Antonia Iazzetti, Walter Cabri, Antonio Ricci & Francesco Gasparrini. (2021) Expanding the Use of Dynamic Electrostatic Repulsion Reversed-Phase Chromatography: An Effective Elution Mode for Peptides Control and Analysis. Molecules 26:14, pages 4348.
Crossref
Crossref
Ajenthen G. Ranjan, Signe Schmidt & Kirsten Nørgaard. (2020) Glucagon for hypoglycaemia treatment in type 1 diabetes. Diabetes/Metabolism Research and Reviews 37:5.
Crossref
Crossref
Martin D. Gelenter, Aurelio J. Dregni, Pu Duan & Mei Hong. (2021) Structurally Based Design of Glucagon Mutants That Inhibit Fibril Formation. Biochemistry 60:25, pages 2033-2043.
Crossref
Crossref
Thomas R. Pieber, Ronnie Aronson, Ulrike Hövelmann, Julie Willard, Leona Plum-Mörschel, Kim M. Knudsen, Benedikte Bandak & Ramin Tehranchi. (2021) Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care 44:6, pages 1361-1367.
Crossref
Crossref
Alon Liberman & Katharine Barnard-Kelly. (2021) Diabetes Technology and the Human Factor. Diabetes Technology & Therapeutics 23:S2, pages S-169-S-178.
Crossref
Crossref
Ryan A. Lafferty, Finbarr P. M. O’Harte, Nigel Irwin, Victor A. Gault & Peter R. Flatt. (2021) Proglucagon-Derived Peptides as Therapeutics. Frontiers in Endocrinology 12.
Crossref
Crossref
Mohammad Sarif Mohiuddin, Tatsuhito Himeno, Yuichiro Yamada, Yoshiaki Morishita, Masaki Kondo, Shin Tsunekawa, Yoshiro Kato, Jiro Nakamura & Hideki Kamiya. (2021) Glucagon Prevents Cytotoxicity Induced by Methylglyoxal in a Rat Neuronal Cell Line Model. Biomolecules 11:2, pages 287.
Crossref
Crossref
SalvaFatima Heba, Uzma Parveen, SaraSana Ayesha Khanum, Maaria Gulnaaz, Maimuna Tabassum & SyedaBatool Safiyya. (2021) Inhaled glucagon: A new hope for severe hypoglycemia in type 1 diabetes. Journal of Diabetology 12:2, pages 114.
Crossref
Crossref
Justin J. Sherman & Jessica L. Lariccia. (2020) Glucagon Therapy: A Comparison of Current and Novel Treatments. Diabetes Spectrum 33:4, pages 347-351.
Crossref
Crossref
Munehide Matsuhisa, Yasushi Takita, Risa Nasu, Yukiko Nagai, Kenji Ohwaki & Hirotaka Nagashima. (2020) Nasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study. Diabetes, Obesity and Metabolism 22:7, pages 1167-1175.
Crossref
Crossref
Jeffrey G. Suico, Ulrike Hövelmann, Shuyu Zhang, Tong Shen, Brandon Bergman, Jennifer Sherr, Eric Zijlstra, Brian M. Frier & Leona Plum-Mörschel. (2020) Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy 11:7, pages 1591-1603.
Crossref
Crossref
Mohan Patil, Nitin J. Deshmukh, Mahesh Patel & Ganesh V. Sangle. (2020) Glucagon-based therapy: Past, present and future. Peptides 127, pages 170296.
Crossref
Crossref
Vivian T. Thieu, Beth D. Mitchell, Oralee J. Varnado & Brian M. Frier. (2020) Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes, Obesity and Metabolism 22:4, pages 469-479.
Crossref
Crossref
William H. PolonskyAddie L. FortmannKenneth E. JohnsonAnh NguyenChristine Beebe. (2020) Hypoglycemic Confidence in the Partners of Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 22:4, pages 249-255.
Crossref
Crossref
Maria J. Pereira, Ketan Thombare, Assel Sarsenbayeva, Prasad G. Kamble, Kristina Almby, Martin Lundqvist & Jan W. Eriksson. (2020) Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes. Molecular and Cellular Endocrinology 503, pages 110696.
Crossref
Crossref
Emily A. O’Reilly, Lourdes V. Cross, Jonathan S. Hayes & Nancy T. Kubiak. (2020) Impact of pharmacist intervention on glucagon prescribing patterns in an outpatient internal medicine teaching clinic. Journal of the American Pharmacists Association 60:2, pages 384-390.
Crossref
Crossref
Toshihiko Aranishi, Yukiko Nagai, Yasushi Takita, Shuyu Zhang & Rimei Nishimura. (2019) Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site. Diabetes Therapy 11:1, pages 197-211.
Crossref
Crossref
Karin D. VanBaak, Laura M. Nally, Ryan T. Finigan, Carrie L. Jurkiewicz, Andre M. Burnier, Barry P. Conrad, Morteza Khodaee & Grant S. Lipman. (2019) Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management. Wilderness & Environmental Medicine 30:4, pages S121-S140.
Crossref
Crossref
Maximilian Kleinert, Stephan Sachs, Kirk M. Habegger, Susanna M. Hofmann & Timo D. Müller. (2019) Glucagon Regulation of Energy Expenditure. International Journal of Molecular Sciences 20:21, pages 5407.
Crossref
Crossref
Damianne Brand-Eubanks. (2019) Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia. Clinical Diabetes 37:4, pages 393-394.
Crossref
Crossref
Sanjay K. Bajpai, M. Janelle Cambron-Mellott, Eugenia Peck, Jiat L. Poon, Qianqian Wang, Beth D. Mitchell, Jane Babrowicz, Christopher J. Child, Nedina K. Raibulet & Kathleen Beusterien. (2019) Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances. Clinical Therapeutics 41:10, pages 2073-2089.e6.
Crossref
Crossref
Colin P. Hawkes, Diva D. De Leon & Michael R. Rickels. (2019) Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia. Current Diabetes Reports 19:10.
Crossref
Crossref
Johannes Pöhlmann, Beth D. Mitchell, Sanjay Bajpai, Beatrice Osumili & William J. Valentine. (2019) Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis. Journal of Diabetes Science and Technology 13:5, pages 910-918.
Crossref
Crossref
Virginia ValentineBrett NewswangerSteve PrestrelskiAnthony D. AndreMark Garibaldi. (2019) Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation. Diabetes Technology & Therapeutics 21:9, pages 522-530.
Crossref
Crossref
Amin GhavamiNejad, Jason Li, Brian Lu, Liwei Zhou, Loretta Lam, Adria Giacca & Xiao Yu Wu. (2019) Glucose‐Responsive Composite Microneedle Patch for Hypoglycemia‐Triggered Delivery of Native Glucagon. Advanced Materials, pages 1901051.
Crossref
Crossref
Sebastian D’hers, Agustín N. Abad Vazquez, Pablo Gurman & Noel M. Elman. (2019) Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon. Drug Delivery and Translational Research 9:3, pages 631-640.
Crossref
Crossref
Jens Kvist Madsen, Lise Giehm & Daniel E. Otzen. (2018) The Use of Surfactants to Solubilise a Glucagon Analogue. Pharmaceutical Research 35:12.
Crossref
Crossref
Larry C Deeb, Hélène Dulude, Cristina B Guzman, Shuyu Zhang, Barry J Reiner, Claude A Piché, Sheetal Pradhan & Xiaotian Michelle Zhang. (2018) A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti. Pediatric Diabetes 19:5, pages 1007-1013.
Crossref
Crossref
Elizabeth R. Seaquist, Hélène Dulude, Xiaotian M. Zhang, Remi Rabasa‐Lhoret, George M. Tsoukas, James R. Conway, Stanley J. Weisnagel, Gregg Gerety, Vincent C. Woo, Shuyu Zhang, Dolorès Carballo, Sheetal Pradhan, Claude A. Piché & Cristina B. Guzman. (2018) Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting. Diabetes, Obesity and Metabolism 20:5, pages 1316-1320.
Crossref
Crossref
Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, Francesca Macchi, Daniela Lamers, Birgit Kronshage, Daniél Vega Møller & Tim Heise. (2018) Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care 41:3, pages 531-537.
Crossref
Crossref
Satya Dash, Changting Xiao, Priska Stahel, Khajag Koulajian, Adria Giacca & Gary F. Lewis. (2017) Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp. Diabetes, Obesity and Metabolism 20:2, pages 328-334.
Crossref
Crossref
Anna Demartis, Armin Lahm, Licia Tomei, Elisa Beghetto, Valentina Di Biasio, Federica Orvieto, Francesco Frattolillo, Paul E. Carrington, Sheena Mumick, Brian Hawes, Elisabetta Bianchi, Anandan Palani & Antonello Pessi. (2018) Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library. Scientific Reports 8:1.
Crossref
Crossref
Takayuki Higashiyama, Midori Umekawa, Masaya Nagao, Toshihiko Katoh, Hisashi Ashida & Kenji Yamamoto. (2018) Chemo-enzymatic synthesis of the glucagon containing N-linked oligosaccharide and its characterization. Carbohydrate Research 455, pages 92-96.
Crossref
Crossref
Michael Khalemsky & David G. Schwartz. (2017) Emergency Response Community Effectiveness: A simulation modeler for comparing Emergency Medical Services with smartphone-based Samaritan response. Decision Support Systems 102, pages 57-68.
Crossref
Crossref
Jean-François YaleHélène DuludeMarc EgethClaude A. PichéMartin LafontaineDolorès CarballoRebecca MargoliesEmily DissingerAdam R. ShamesNicole KaplowitzMichelle Xiaotian ZhangShuyu ZhangCristina B. Guzman. (2017) Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study. Diabetes Technology & Therapeutics 19:7, pages 423-432.
Crossref
Crossref
Frédéric Lapostolle, Nadia Hamdi, Majed Barghout, Louis Soulat, Anna Faucher, Yves Lambert, Nicolas Peschanski, Agnès Ricard-Hibon, Carine Chassery, Maryline Roti, Vincent Bounes, Guillaume Debaty, Tarak Mokni, Gérald Egmann, Pierre-Arnaud Fort, Karim Boudenia, Laurent Alayrac, Mohamed Safraou, Michel Galinski & Frédéric Adnet. (2016) Diabetes education of patients and their entourage: out-of-hospital national study (EDUCATED 2). Acta Diabetologica 54:4, pages 353-360.
Crossref
Crossref
Ellen Cobb, Nina Watson, Jana Wardian, Connie Morrow & Tom Sauerwein. (2016) Glucagon Kits. AADE in Practice 5:1, pages 12-17.
Crossref
Crossref
Santosh Sanagapalli, Kriti Agnihotri, Rupert Leong & Crispin John Corte. (2016) Antispasmodic drugs in colonoscopy: a review of their pharmacology, safety and efficacy in improving polyp detection and related outcomes. Therapeutic Advances in Gastroenterology 10:1, pages 101-113.
Crossref
Crossref
Christopher G. Thanos, Jason L. Gaglia & Felicia W. Pagliuca. 2017. Cell Therapy. Cell Therapy
19
52
.
K. Konrad, C. Vogel, E. Bollow, M. Fritsch, K. Lange, B. Bartus & R.W. Holl. (2016) Current practice of diabetes education in children and adolescents with type 1 diabetes in Germany and Austria: analysis based on the German/Austrian DPV database. Pediatric Diabetes 17:7, pages 483-491.
Crossref
Crossref
H. K. Reiband, S. Schmidt, A. Ranjan, J. J. Holst, S. Madsbad & K. Nørgaard. (2015) Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews 31:7, pages 672-679.
Crossref
Crossref
Dick RylanderJrJr. (2014) Treating Severe Hypoglycemia. Journal of Diabetes Science and Technology 9:1, pages 34-37.
Crossref
Crossref
Stephanie T. Chung & Morey W. Haymond. (2014) Minimizing Morbidity of Hypoglycemia in Diabetes. Journal of Diabetes Science and Technology 9:1, pages 44-51.
Crossref
Crossref
Trang T. Ly, Alan J.M. Brnabic, Andrew Eggleston, Athena Kolivos, Margaret E. McBride, Rudolf Schrover & Timothy W. Jones. (2014) A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes. Value in Health 17:5, pages 561-569.
Crossref
Crossref
Takashi MurataKentaro OkazakiKatsuyuki YanagisawaKenichi YamadaNobuichi KuribayashiYasuo TotsukaToru HiyoshiMotoji NakaMasatake SugimotoYuji AokiMasako WakiMiyuki FuruyaHaruko KitaokaMariko OishiIkki ShimizuHiroaki MiyaokaToshikazu YamamotoKazunori YamadaNaoki Sakane. (2013) Glucagon Underutilized Among Type 1 Diabetes Mellitus Patients in Japan. Diabetes Technology & Therapeutics 15:9, pages 748-750.
Crossref
Crossref
Nicholas Caputo, Jessica R. Castle, Colin P. Bergstrom, Julie M. Carroll, Parkash A. Bakhtiani, Melanie A. Jackson, Charles T. RobertsJr.Jr., Larry L. David & W. Kenneth Ward. (2013) Mechanisms of glucagon degradation at alkaline pH. Peptides 45, pages 40-47.
Crossref
Crossref
Stijn J.M. Niessen. (2012) Glucagon: Are we missing a (life-saving) trick?. Journal of Veterinary Emergency and Critical Care 22:5, pages 523-525.
Crossref
Crossref